Andrew Allen

Andrew trained in Medicine at Oxford University, practicing as a nephrologist (focus on transplantation and immune-mediated glomerulonephritis) at Hammersmith Hospital in London before completing a Ph.D. in Immunology at Imperial College, London. He moved into industry at McKinsey & Co and began focusing on Oncology R&D strategy, which he continued in development leadership roles at Abbott and Chiron.

He was Chief Medical Officer at Pharmion, developer of Vidaza worldwide and Thalidomide in Europe (acquired by Celgene in 2008), and was then co-founder and Chief Medical Officer/EVP Pre-Clinical Development at Clovis Oncology, which had its first product (PARP inhibitor) approved by FDA in Dec 2016. Andrew sits on the board of Epizyme (NASDAQ: EPZM), Sierra Oncology (NASDAQ:SRRA), TCR2 Therapeutics (NASDAQ: TCRR) and Revitope. Previously he was on the board of Cell Design Labs (private) until it was acquired by Gilead in 2018.